Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging.
circulating ensembles of tumor-associated cells (C-ETACs)
circulating tumor cells (CTCs)
diagnosis
diagnostic triaging
liquid biopsy
noninvasive
solid organ cancers
Journal
Cancer cytopathology
ISSN: 1934-6638
Titre abrégé: Cancer Cytopathol
Pays: United States
ID NLM: 101499453
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
03
08
2020
revised:
29
08
2020
accepted:
08
09
2020
pubmed:
1
10
2020
medline:
31
7
2021
entrez:
30
9
2020
Statut:
ppublish
Résumé
Histopathologic examination (HPE) of tumor tissue obtained by invasive biopsy is the standard for cancer diagnosis but is resource-intensive and has been associated with procedural risks. The authors demonstrate that immunocytochemistry (ICC) profiling of circulating ensembles of tumor-associated cells (C-ETACs) can noninvasively provide diagnostic guidance in solid organ cancers. The clinical performance of this approach was tested on blood samples from 30,060 individuals, including 9416 individuals with known cancer; 6725 symptomatic individuals with suspected cancer; and 13,919 asymptomatic individuals with no prior diagnosis of cancer. C-ETACs were harvested from peripheral blood and profiled by ICC for organ-specific and subtype-specific markers relevant to the cancer type. ICC profiles were compared with HPE diagnoses to determine concordance. The presence of malignancy was confirmed by the detection of C-ETACs in 91.8% of the 9416 individuals with previously known cancer. Of the 6725 symptomatic individuals, 6025 were diagnosed with cancer, and 700 were diagnosed with benign conditions; C-ETACs were detected in 92.6% of samples from the 6025 individuals with cancer. In a subset of 3509 samples, ICC profiling of C-ETACs for organ-specific and subtype-specific markers was concordant with HPE findings in 93.1% of cases. C-ETACs were undetectable in 95% of samples from the 700 symptomatic individuals who had benign conditions and in 96.3% of samples from the 13,919 asymptomatic individuals. C-ETACs were ubiquitous (>90%) in various cancers and provided diagnostically relevant information in the majority (>90%) of cases. This is the first comprehensive report on the feasibility of ICC profiling of C-ETACs to provide pan-cancer diagnostic guidance with accuracy comparable to that of HPE.
Sections du résumé
BACKGROUND
Histopathologic examination (HPE) of tumor tissue obtained by invasive biopsy is the standard for cancer diagnosis but is resource-intensive and has been associated with procedural risks. The authors demonstrate that immunocytochemistry (ICC) profiling of circulating ensembles of tumor-associated cells (C-ETACs) can noninvasively provide diagnostic guidance in solid organ cancers.
METHODS
The clinical performance of this approach was tested on blood samples from 30,060 individuals, including 9416 individuals with known cancer; 6725 symptomatic individuals with suspected cancer; and 13,919 asymptomatic individuals with no prior diagnosis of cancer. C-ETACs were harvested from peripheral blood and profiled by ICC for organ-specific and subtype-specific markers relevant to the cancer type. ICC profiles were compared with HPE diagnoses to determine concordance.
RESULTS
The presence of malignancy was confirmed by the detection of C-ETACs in 91.8% of the 9416 individuals with previously known cancer. Of the 6725 symptomatic individuals, 6025 were diagnosed with cancer, and 700 were diagnosed with benign conditions; C-ETACs were detected in 92.6% of samples from the 6025 individuals with cancer. In a subset of 3509 samples, ICC profiling of C-ETACs for organ-specific and subtype-specific markers was concordant with HPE findings in 93.1% of cases. C-ETACs were undetectable in 95% of samples from the 700 symptomatic individuals who had benign conditions and in 96.3% of samples from the 13,919 asymptomatic individuals.
CONCLUSIONS
C-ETACs were ubiquitous (>90%) in various cancers and provided diagnostically relevant information in the majority (>90%) of cases. This is the first comprehensive report on the feasibility of ICC profiling of C-ETACs to provide pan-cancer diagnostic guidance with accuracy comparable to that of HPE.
Identifiants
pubmed: 32996712
doi: 10.1002/cncy.22366
pmc: PMC7984349
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-238Informations de copyright
© 2020 Datar Cancer Genetics Ltd. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Trends Pharmacol Sci. 2019 Mar;40(3):172-186
pubmed: 30736982
Indian J Urol. 2014 Apr;30(2):214-8
pubmed: 24744523
J Urol. 2015 Apr;193(4):1178-84
pubmed: 25444971
Clin Radiol. 2011 Nov;66(11):1007-14
pubmed: 21784421
Int J Cancer. 2020 Jun 15;146(12):3485-3494
pubmed: 31785151
J Clin Oncol. 2005 Mar 1;23(7):1420-30
pubmed: 15735118
Clin Cancer Res. 2007 Dec 1;13(23):7053-8
pubmed: 18056182
J Clin Oncol. 2008 Jul 1;26(19):3213-21
pubmed: 18591556
J Clin Oncol. 2012 Feb 20;30(6):587-92
pubmed: 22124102
Ther Adv Med Oncol. 2010 Nov;2(6):351-65
pubmed: 21789147
Cancer Res. 2018 Aug 15;78(16):4731-4744
pubmed: 29915159
World Neurosurg. 2015 Oct;84(4):1084-9
pubmed: 26008141
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Transplantation. 2002 Feb 27;73(4):553-5
pubmed: 11889428
BMC Pulm Med. 2012 Feb 06;12:2
pubmed: 22309812
Open Access Maced J Med Sci. 2019 Mar 29;7(6):992-995
pubmed: 30976347
Theranostics. 2013 Apr 23;3(6):377-94
pubmed: 23781285
Lancet. 2016 Sep 3;388(10048):1002-11
pubmed: 27598680
Arch Pathol Lab Med. 2020 Jun;144(6):706-724
pubmed: 31714809
Radiology. 2004 Jun;231(3):845-9
pubmed: 15163821
Clin Colorectal Cancer. 2018 Mar;17(1):80-83
pubmed: 29195807
Wien Klin Wochenschr. 2018 Apr;130(7-8):288-292
pubmed: 29362884
BMC Cancer. 2014 Mar 28;14:226
pubmed: 24674711
Open Access Maced J Med Sci. 2015 Jun 15;3(2):241-4
pubmed: 27275228
Eur Radiol. 2008 Jul;18(7):1356-63
pubmed: 18351356
J Cell Physiol. 2010 Jan;222(1):42-9
pubmed: 19798694
AJR Am J Roentgenol. 2011 Jun;196(6):W678-82
pubmed: 21606253
Ann Oncol. 2017 Mar 1;28(3):468-477
pubmed: 27998963
Adolesc Health Med Ther. 2015 Sep 02;6:159-63
pubmed: 26366109
Plast Reconstr Surg. 2007 Jul;120(1):13e-19e
pubmed: 17572540
Micromachines (Basel). 2018 Jul 14;9(7):
pubmed: 30424286
Clin Cancer Res. 2015 Jun 1;21(11):2487-98
pubmed: 25381338
Cancer Cytopathol. 2021 Mar;129(3):226-238
pubmed: 32996712
J Hematol Oncol. 2019 May 14;12(1):48
pubmed: 31088479
Cancer Cytopathol. 2017 Oct;125(10):748-756
pubmed: 28837268
Clin Breast Cancer. 2016 Jun;16(3):e43-8
pubmed: 26642811
Turk J Urol. 2013 Mar;39(1):6-11
pubmed: 26328070
Semin Plast Surg. 2013 Feb;27(1):23-5
pubmed: 24872735